• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

涉及多个相关必赢比较的试验的样本量。

Sample sizes for trials involving multiple correlated must-win comparisons.

作者信息

Julious Steven A, McIntyre Nikki E

机构信息

University of Sheffield-Medical Statistics Group, Health Services Research, ScHARR University of Sheffield, Regent Court, 30 Regent Steet, Sheffield, Yorkshire S14DA, United Kingdom.

出版信息

Pharm Stat. 2012 Mar-Apr;11(2):177-85. doi: 10.1002/pst.515. Epub 2012 Mar 1.

DOI:10.1002/pst.515
PMID:22383136
Abstract

In Clinical trials involving multiple comparisons of interest, the importance of controlling the trial Type I error is well-understood and well-documented. Moreover, when these comparisons are themselves correlated, methodologies exist for accounting for the correlation in the trial design, when calculating the trial significance levels. However, less well-documented is the fact that there are some circumstances where multiple comparisons affect the Type II error rather than the Type I error, and failure to account for this, can result in a reduction in the overall trial power. In this paper, we describe sample size calculations for clinical trials involving multiple correlated comparisons, where all the comparisons must be statistically significant for the trial to provide evidence of effect, and show how such calculations have to account for multiplicity in the Type II error. For the situation of two comparisons, we provide a result which assumes a bivariate Normal distribution. For the general case of two or more comparisons we provide a solution using inflation factors to increase the sample size relative to the case of a single outcome. We begin with a simple case of two comparisons assuming a bivariate Normal distribution, show how to factor in correlation between comparisons and then generalise our findings to situations with two or more comparisons. These methods are easy to apply, and we demonstrate how accounting for the multiplicity in the Type II error leads, at most, to modest increases in the sample size.

摘要

在涉及多个感兴趣比较的临床试验中,控制试验I型错误的重要性已得到充分理解和记录。此外,当这些比较本身存在相关性时,在计算试验显著性水平时,存在一些方法可用于在试验设计中考虑相关性。然而,记录较少的一个事实是,在某些情况下,多重比较会影响II型错误而非I型错误,若未考虑这一点,可能会导致整体试验效能降低。在本文中,我们描述了涉及多个相关比较的临床试验的样本量计算方法,其中所有比较都必须具有统计学显著性,试验才能提供效应证据,并展示了此类计算如何考虑II型错误中的多重性。对于两个比较的情况,我们给出了一个假设二元正态分布的结果。对于两个或更多比较的一般情况,我们提供了一种使用膨胀因子的解决方案,以相对于单个结果的情况增加样本量。我们从假设二元正态分布的两个比较的简单情况开始,展示如何考虑比较之间的相关性,然后将我们的发现推广到两个或更多比较的情况。这些方法易于应用,并且我们展示了考虑II型错误中的多重性最多只会导致样本量适度增加。

相似文献

1
Sample sizes for trials involving multiple correlated must-win comparisons.涉及多个相关必赢比较的试验的样本量。
Pharm Stat. 2012 Mar-Apr;11(2):177-85. doi: 10.1002/pst.515. Epub 2012 Mar 1.
2
A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.一种用于具有多个共同主要连续终点的临床试验中样本量计算的简便公式。
Pharm Stat. 2012 Mar-Apr;11(2):118-28. doi: 10.1002/pst.505.
3
Power and sample size when multiple endpoints are considered.考虑多个终点时的检验效能和样本量。
Pharm Stat. 2007 Jul-Sep;6(3):161-70. doi: 10.1002/pst.301.
4
Multiple-arm superiority and non-inferiority designs with various endpoints.具有多种终点的多臂优效性和非劣效性设计。
Pharm Stat. 2007 Jan-Mar;6(1):43-52. doi: 10.1002/pst.242.
5
Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.具有多个共同主要相关终点的优效性临床试验中的样本量确定
J Biopharm Stat. 2011 Jul;21(4):650-68. doi: 10.1080/10543406.2011.551329.
6
Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.多重性调整后的样本量要求:一种通过Bonferroni调整来维持统计功效的策略。
J Clin Psychiatry. 2004 Nov;65(11):1511-4.
7
Multiplicity and flexibility in clinical trials.临床试验中的多样性与灵活性。
Pharm Stat. 2007 Jul-Sep;6(3):205-16. doi: 10.1002/pst.302.
8
Evaluation of the statistical power for multiple tests: a case study.多重检验的统计功效评估:一个案例研究
Pharm Stat. 2009 Jan-Mar;8(1):5-11. doi: 10.1002/pst.319.
9
Group-sequential methods for adaptive seamless phase II/III clinical trials.用于适应性无缝II/III期临床试验的序贯分组方法。
J Biopharm Stat. 2011 Jul;21(4):787-801. doi: 10.1080/10543406.2011.551335.
10
Balanced two-stage designs for phase II clinical trials.用于II期临床试验的平衡两阶段设计
Clin Trials. 2007;4(5):514-24. doi: 10.1177/1740774507084102.

引用本文的文献

1
Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints.利用混合结局共同主要结局、多个主要结局和复合结局的潜变量模型进行样本量估计。
Stat Med. 2022 Jun 15;41(13):2303-2316. doi: 10.1002/sim.9356. Epub 2022 Feb 23.
2
Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints.比较三种用于具有多个连续共同主要终点的非劣效性疫苗试验的样本量计算方法。
Hum Vaccin Immunother. 2019;15(1):256-263. doi: 10.1080/21645515.2018.1514221. Epub 2018 Oct 4.
3
Effects of a 6-month self-rehabilitation programme in addition to botulinum toxin injections and conventional physiotherapy on limitations of patients with spastic hemiparesis following stroke (ADJU-TOX): protocol study for a randomised controlled, investigator blinded study.
除肉毒杆菌毒素注射和传统物理治疗外,一项为期6个月的自我康复计划对中风后痉挛性偏瘫患者功能受限的影响(ADJU-TOX):一项随机对照、研究者盲法研究的方案研究
BMJ Open. 2018 Aug 30;8(8):e020915. doi: 10.1136/bmjopen-2017-020915.
4
Effect of botulinum toxin injection on length and force of the rectus femoris and triceps surae muscles during locomotion in patients with chronic hemiparesis (FOLOTOX).肉毒杆菌毒素注射对慢性偏瘫患者运动过程中股直肌和小腿三头肌长度及力量的影响(FOLOTOX研究)
BMC Neurol. 2018 Aug 2;18(1):104. doi: 10.1186/s12883-018-1110-8.
5
Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.具有共同主要终点的临床试验的设计、数据监测与分析:综述
J Biopharm Stat. 2018;28(1):28-51. doi: 10.1080/10543406.2017.1378668. Epub 2017 Oct 30.
6
Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts.使用多个共同主要二元相对风险对比比较两种干预措施时临床试验中的样本量考量
Stat Biopharm Res. 2015 Jun 24;7(2):81-94. doi: 10.1080/19466315.2015.1006373.
7
Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.具有多个共同主要结局的临床试验中的序贯分组策略
Stat Biopharm Res. 2015;7(1):36-54. doi: 10.1080/19466315.2014.1003090.
8
Sample size determination in group-sequential clinical trials with two co-primary endpoints.具有两个共同主要终点的序贯临床试验中的样本量确定
Stat Med. 2014 Jul 30;33(17):2897-913. doi: 10.1002/sim.6154. Epub 2014 Mar 27.
9
Sample size determinations in original research protocols for randomised clinical trials submitted to UK research ethics committees: review.随机临床试验原始研究方案中样本量的确定:综述。
BMJ. 2013 Mar 21;346:f1135. doi: 10.1136/bmj.f1135.